Phase I clinical trial of oral 2-methoxyestradiol, an antiangiogenic and apoptotic agent, in patients with solid tumors.

@article{Dahut2006PhaseIC,
  title={Phase I clinical trial of oral 2-methoxyestradiol, an antiangiogenic and apoptotic agent, in patients with solid tumors.},
  author={William L. Dahut and Nehal J. Lakhani and James L. Gulley and Philip M. Arlen and Elise C. Kohn and Herbert L Kotz and Debbie McNally and Allyson Parr and Diana Phuong-Anh Nguyen and Sherry X. Yang and Seth Steinberg and J{\"u}rgen Venitz and Alex Sparreboom and William D. Figg},
  journal={Cancer biology & therapy},
  year={2006},
  volume={5 1},
  pages={22-7}
}
PURPOSE To determine the maximum-tolerated dose (MTD) and toxicity profile of the novel anticancer agent, 2-methoxyestradiol (2ME2) administered orally, in patients with solid tumors. MATERIALS AND METHODS Twenty patients with refractory solid tumors were enrolled. 2ME2 was given orally starting at 400 mg bid with dose escalation until 3000 mg bid. Tumor biopsies were taken before and after starting the drug to assess for microvessel density by CD 31 and cell proliferation by Ki67… CONTINUE READING

Citations

Publications citing this paper.
Showing 1-10 of 63 extracted citations

Phase I trial of 2-methoxyestradiol NanoCrystal dispersion in advanced solid malignancies.

Clinical cancer research : an official journal of the American Association for Cancer Research • 2009
View 5 Excerpts
Highly Influenced

Similar Papers

Loading similar papers…